Dr. Elizabeth O. Hexner, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 128
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Missouri, Columbia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
PA license MD419925
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
- Pennsylvania Hospital Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 128
- Services billed
- 284
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 82 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 72 | 56 |
| Established patient office or other outpatient visit, 40-54 minutes | 67 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 51 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 201 |
| Hydroxyurea Other prescribers in Philadelphia, PA | 107 |
| Ayvakit (avapritinib) | 75 |
| Famotidine Other prescribers in Philadelphia, PA | 37 |
| Besremi (ropeginterferon alfa-2b-njft) | 27 |
| Escitalopram Oxalate Other prescribers in Philadelphia, PA | 21 |
| Acyclovir Other prescribers in Philadelphia, PA | 17 |
| Cromolyn Sodium | 14 |
| Levothyroxine Sodium Other prescribers in Philadelphia, PA | 14 |
| Sprycel (dasatinib) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $2,332 in total to this clinician.
| Blueprint Medicines Corporation | $2,332 |
|---|
| Honoraria | $2,332 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Blueprint Medicines Corporation Jun 13, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $2,332 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $40,696 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic…
National Marrow Donor Program - M20-178 - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis
AbbVie Inc. - (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation · Completed · NCT03580655 - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.